Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

487.61 -2.63 (-0.54%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	327,025
Open	484.33
Bid (Size)	482.03 (40)
Ask (Size)	495.00 (200)
Prev. Close	490.24
Today's Range	484.33 - 494.08
52wk Range	375.61 - 609.35
Shares Outstanding	44,891,523
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗

September 03, 2026

Via Chartmill

3 Profitable Stocks We’re Skeptical Of

September 03, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Performance

YTD	-1.8%	-1.8%
1 Month	-6.0%	-6.0%
3 Month	-11.3%	-11.3%
6 Month	+2.0%	+2.0%
1 Year	+28.2%	+28.2%

More News

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

September 02, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

September 01, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

August 28, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns ↗

August 20, 2026

Via Chartmill

United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗

August 13, 2026

Via Chartmill

United Therapeutics (NASDAQ:UTHR) Tumbles as Q2 Revenue Misses Despite EPS Beat ↗

August 05, 2026

Via Chartmill

3 Cash-Producing Stocks We Keep Off Our Radar

August 26, 2026

Via StockStory

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

August 24, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

August 17, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions

August 12, 2026

Via StockStory

UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures

August 06, 2026

Via StockStory

United Therapeutics Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales

August 05, 2026

Via StockStory

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

August 05, 2026

From United Therapeutics Corporation

Via Business Wire

Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow

August 03, 2026

Via StockStory

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

July 29, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors? ↗

July 28, 2026

Via The Motley Fool

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

July 23, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

July 22, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Acquires Thymmune Therapeutics

July 02, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion

June 29, 2026

From United Therapeutics Corporation

Via Business Wire

Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)

June 22, 2026

Via StockStory

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?

Yes, United Therapeutics Corporation - Common Stock is publicly traded.

What exchange does United Therapeutics Corporation - Common Stock trade on?

United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for United Therapeutics Corporation - Common Stock?

The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market

What is the current price of United Therapeutics Corporation - Common Stock?

The current price of United Therapeutics Corporation - Common Stock is 487.61

When was United Therapeutics Corporation - Common Stock last traded?

The last trade of United Therapeutics Corporation - Common Stock was at 09/04/26 04:00 PM ET

What is the market capitalization of United Therapeutics Corporation - Common Stock?

The market capitalization of United Therapeutics Corporation - Common Stock is 21.89B

How many shares of United Therapeutics Corporation - Common Stock are outstanding?

United Therapeutics Corporation - Common Stock has 22B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.